Key facts
- This page summarizes Frederick Pierce II's Form 3 filing for Salarius Pharmaceuticals, Inc. (SLRX).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 24 Nov 2025, 07:59.
Frederick Pierce II - 12 Nov 2025 Form 3 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)
- Reporting relationship
- Chief Executive Office
- Issuer ticker
- SLRX
- Reported as of
- 12 Nov 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/Mark Rosenblum, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Frederick Pierce II filed Form 3 for Salarius Pharmaceuticals, Inc. (SLRX) on 24 Nov 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001229055
Primary reporting owner
PIERCE FREDERICK II
- Relationship
- Chief Executive Office
- Address
- 2450 HOLCOMBE BLVD STE X, HOUSTON
- Signature
- /s/Mark Rosenblum, as Attorney-in-Fact
- Signature date
- 24 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,666
- Date
- 12 Nov 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLRX
holding
Derivative
Series A Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,619
- Exercise price
- Footnotes
- F1
SLRX
holding
Derivative
Series A Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,666
- Exercise price
- $1.50
SLRX
holding
Derivative
Series B Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,666
- Exercise price
- $1.50
SLRX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,061
- Exercise price
- $4.94
- Footnotes
- F2
SLRX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Nov 2025
- Ownership
- By: Frederick E. Pierce II Living Trust date January 28, 2011 Pierce
- Underlying class
- Common Stock
- Underlying amount
- 8,318
- Exercise price
- $50.26
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Series A Preferred Shares are convertible into 141,734 shares of Common Stock. The Series A Preferred Shares have no expiration date, and convert automatically into shares of Common Stock following stockholder approval and satisfaction of certain Nasdaq listing standards.
Footnote F2
The Stock Options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.
SEC remarks
Exhibit 24, Power of Attorney, is attached.